肾透明细胞癌行保留肾单位手术后复发风险预测模型的构建

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (3): 409-414.

肾透明细胞癌行保留肾单位手术后复发风险预测模型的构建

陈志刚^1,2#, 洪鹏^2#, 杨斌², 田晓军², 王国良², 张树栋², 马潞林^2*

1.北京大学医学部,北京 100191;
2.北京大学第三医院泌尿外科, 北京 100191

收稿日期:2020-11-06 修回日期:2020-12-24 出版日期:2021-03-05 发布日期:2021-03-01
通讯作者: ^*malulinpku@163.com
作者简介:^#对本文有相同贡献

Constructing a risk predictive model for recurrence following nephron-sparing surgery in the treatment of clear cell renal cell carcinoma

CHEN Zhi-gang^1,3#, HONG Peng^2#, YANG Bin², TIAN Xiao-jun², WANG Guo-liang², ZHANG Shu-dong², MA Lu-lin^2*

1. Peking University Health Science Center, Beijing 100191;
2. Department of Urology, Peking University Third Hospital, Beijing 100191, China

Received:2020-11-06 Revised:2020-12-24 Online:2021-03-05 Published:2021-03-01
Contact: ^*malulinpku@163.com

摘要/Abstract

摘要： 目的探讨局限性肾透明细胞癌(ccRCC)患者行保留肾单位手术(NSS)后复发的相关危险因素,建立NSS术后5年复发风险的预测模型。方法回顾性分析2006年1月至2019年7月于北京大学第三医院行NSS患者的临床资料,采用单因素和多因素回归分析影响ccRCC术后复发的相关因素,并建立预测NSS术后5年复发风险的列线图。结果共计795例经病理诊断为ccRCC的患者纳入研究。随访过程中,17例发生复发,复发率为2.1%,中位复发时间为35.7个月。在单因素回归分析中,BMI(HR=4.102,P＜0.05)、动脉阻断时间(HR=0.194,P＜0.01)和肿瘤坏死或肉瘤样改变(HR=5.160,P＜0.01)与术后无复发生存相关。多因素回归分析显示这3个因素是无复发生存的独立影响因素。采用内部验证法对复发风险列线图的准确性进行验证,C指数为0.843。结论 BMI、动脉阻断时间、肿瘤坏死或肉瘤样改变是影响ccRCC术后复发的独立因素。本研究建立了一个相对准确的预测复发风险的模型,这将有助于为ccRCC患者提供个性化的治疗。

关键词: 肾透明细胞癌, 保留肾单位手术, 复发, 预后, 列线图

Abstract: Objective To detect factors associated with recurrence after nephron-sparing surgery (NSS) in patients with localized clear cell renal cell carcinoma (ccRCC), and to construct a model for predicting the recurrence risk in five years following NSS. Methods Data of the patients who underwent NSS for renal occupied lesions between January 2006 and July 2019 at Peking University Third Hospital were retrospectively analyzed. Univariate and multivariate logistic regression analyses were used to assess the factors associated with recurrence of ccRCC after NSS, and a nomogram was established to predict recurrence risk in 5 years following NSS. Results Totally 795 patients who were pathologically diagnosed with ccRCC were included in the study. Recurrence occurred in 17 cases, with the recurrence rate 2.1%. The median time to relapse was 35.7 months. In the univariable analysis, BMI (HR=4.102, P＜ 0.05), the artery blocking time (HR=0.194, P＜ 0.01) and tumor necrosis or sarcomatoid change (HR=5.160, P＜ 0.01) were associated with recurrence-free survival of the ccRCC patients after NSS. The multivariate analysis showed that these three factors were independent factors of recurrence. The accuracy of our nomogram for recurrence risk was verified using internal validation, and the value of c-index was 0.843. Conclusions BMI, artery blocking time and tumor necrosis or sarcomatoid change were independent factors for recurrence following NSS in the ccRCC patients. An accurate model to predict the recurrence risk is constructed, which may help to provide personalized managements for the aforementioned patients after NSS.

Key words: clear cell renal cell carcinoma, nephron-sparing surgery, recurrence, prognosis, nomogram

中图分类号:

R692.9

陈志刚, 洪鹏, 杨斌, 田晓军, 王国良, 张树栋, 马潞林. 肾透明细胞癌行保留肾单位手术后复发风险预测模型的构建[J]. 基础医学与临床, 2021, 41(3): 409-414.

CHEN Zhi-gang, HONG Peng, YANG Bin, TIAN Xiao-jun, WANG Guo-liang, ZHANG Shu-dong, MA Lu-lin. Constructing a risk predictive model for recurrence following nephron-sparing surgery in the treatment of clear cell renal cell carcinoma[J]. Basic & Clinical Medicine, 2021, 41(3): 409-414.

参考文献

[1] Lane BR, Campbell SC, Gill IS. 10-year oncologic outcomes after laparoscopic and open partial nephrectomy[J]. J Urol, 2013, 190: 44-49.
[2] Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma[J]. J Urol, 2001, 166:63-67.
[3] Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study[J]. J Clin Oncol, 2004, 22:3316-3322.
[4] Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score[J]. J Urol, 2002, 168:2395-2400.
[5] Yaycioglu O, Roberts WW, Chan T, et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model[J]. Urology, 2001, 58:141-145.
[6] Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma[J]. BJU Int, 2003, 92:901-905.
[7] Zhang Z, Lin E, Zhuang H, et al. Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma[J]. Cancer Cell Int, 2020, 20:27. doi: 10.1186/s12935-020-1113-6.
[8] Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer[J]. Nat Rev Urol, 2010, 7:245-257.
[9] Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma[J]. J Natl Cancer Inst, 2013, 105:1862-1870.
[10] Donat SM, Salzhauer EW, Mitra N, et al. Impact of body mass index on survival of patients with surgically treated renal cell carcinoma[J]. J Urol, 2006, 175:46-52.
[11] Steffens S, Ringe KI, Schroeer K, et al. German Renal Cell Tumor Network. Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study[J]. Int J Urol, 2013, 20:585-592.
[12] Komura K, Inamoto T, Black PC, et al. Prognostic significance of body mass index in Asian patients with localized renal cell carcinoma[J]. Nutr Cancer, 2011, 63:908-915.
[13] Volpe A, Blute ML, Ficarra V, et al. Renal ischemia and function after partial nephrectomy: a collaborative review of the literature[J]. Eur Urol, 2015, 68:61-74.
[14] Brookman-May S, May M, Shariat SF, et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project)[J]. Eur Urol, 2013, 64:472-477.
[15] Zhang L, Wu B, Zha Z, et al. The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and metaanalysis[J]. Cancer Manag Res, 2018, 10:1687-1703.